Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising effects. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare practitioners. While tirzepatide has been cleared by regulatory agencies, its expensive nature presents a significant barrier to many.